Literature DB >> 21987032

The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy.

Leah Kleinman1, Katy Benjamin, Hema Viswanathan, Maria Stoeckl Mattera, Linda Bosserman, Douglas W Blayney, Dennis A Revicki.   

Abstract

PURPOSE: To develop a patient-reported outcome instrument for measuring anemia symptoms and their impact in patients with chemotherapy-induced anemia (CIA).
METHODS: Qualitative research was conducted using six focus groups and 24 interviews with 46 CIA patients, eight interviews in patients receiving chemotherapy with no CIA history and two interviews in patients successfully treated for CIA. Atlas.ti 5.0 was used to organize key concepts. Cognitive interviews with 16 CIA patients and assessment of relevance of each item to CIA by 10 clinicians were also conducted to evaluate content validity.
RESULTS: Most CIA patients were white (76%) and female (83%), and the average age was 60 years. The most common cancer types were breast cancer (54%) and lung cancer (17%). Tiredness was the most prevalent symptom and rated as the most important by 83% of CIA patients; weakness, shortness of breath, lightheadedness, and dizziness were ranked next in importance. The final anemia impact measure (AIM) contains: (1) daily CIA symptom diary (9 items), and (2) impact of CIA-related tiredness (29 items covering daily living activities, social activities, cognitive function, and emotions). Cognitive interviews found that the AIM was relevant and easy to understand.
CONCLUSIONS: The AIM assesses important patient-perceived CIA symptoms and their impact and was developed using extensive patient qualitative data.

Entities:  

Mesh:

Year:  2011        PMID: 21987032     DOI: 10.1007/s11136-011-0034-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  9 in total

1.  Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.

Authors:  Javier de Castro; Amalio Ordóñez; Dolores Isla; Alfredo Sánchez; Antonio Arrivi; José Luis Manzano; Manuel González Barón
Journal:  Cancer Chemother Pharmacol       Date:  2006-07-28       Impact factor: 3.333

2.  The economic burden of anemia in cancer patients receiving chemotherapy.

Authors:  Gary H Lyman; Ernst R Berndt; Joel D Kallich; M Haim Erder; William H Crown; Stacey R Long; Howard Lee; Xue Song; Stan N Finkelstein
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

3.  Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

Authors:  J L Gabrilove; C S Cleeland; R B Livingston; B Sarokhan; E Winer; L H Einhorn
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

4.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

5.  Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy.

Authors:  Ernst Berndt; Joel Kallich; Anne McDermott; Xiao Xu; Howard Lee; John Glaspy
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Chemotherapy-induced anemia in adults: incidence and treatment.

Authors:  J E Groopman; L M Itri
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

7.  The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials.

Authors:  D Cella; J Kallich; A McDermott; X Xu
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

8.  Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

Authors:  A Bamias; G Aravantinos; C Kalofonos; N Timotheadou; V Siafaka; I Vlahou; D Janinis; D Pectasides; N Pavlidis; G Fountzilas
Journal:  Oncology       Date:  2003       Impact factor: 2.935

9.  Impact of epoetin beta on quality of life in patients with malignant disease.

Authors:  M Boogaerts; B Coiffier; C Kainz
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

  9 in total
  1 in total

Review 1.  Engaging Patients as Partners in Developing Patient-Reported Outcome Measures in Cancer-A Review of the Literature.

Authors:  Natasha Camuso; Prerna Bajaj; Deborah Dudgeon; Gunita Mitera
Journal:  Support Care Cancer       Date:  2016-03-28       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.